Quantitative Proteomics in Lung Cancer

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2017 Jun 16

PMID 28615068

Citations 51

Authors

Chantal Hoi Yin Cheung

Hsueh-Fen Juan

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the most common cause of cancer-related death worldwide, less than 7% of patients survive 10 years following diagnosis across all stages of lung cancer. Late stage of diagnosis and lack of effective and personalized medicine reflect the need for a better understanding of the mechanisms that underlie lung cancer progression. Quantitative proteomics provides the relative different protein abundance in normal and cancer patients which offers the information for molecular interactions, signaling pathways, and biomarker identification. Here we introduce both theoretical and practical applications in the use of quantitative proteomics approaches, with principles of current technologies and methodologies including gel-based, label free, stable isotope labeling as well as targeted proteomics. Predictive markers of drug resistance, candidate biomarkers for diagnosis, and prognostic markers in lung cancer have also been discovered and analyzed by quantitative proteomic analysis. Moreover, construction of protein networks enables to provide an opportunity to interpret disease pathway and improve our understanding in cancer therapeutic strategies, allowing the discovery of molecular markers and new therapeutic targets for lung cancer.

Citing Articles

Integration of proteomics profiling data to facilitate discovery of cancer neoantigens: a survey.

Luo S, Peng H, Shi Y, Cai J, Zhang S, Shao N Brief Bioinform. 2025; 26(2).

PMID: 40052441 PMC: 11886573. DOI: 10.1093/bib/bbaf087.

Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.

Wan X, Zhang C, Kang M, Rossi A, Goto T, Seetharamu N Transl Cancer Res. 2025; 14(1):569-583.

PMID: 39974402 PMC: 11833388. DOI: 10.21037/tcr-2024-2443.

NUP155 and NDC1 interaction in NSCLC: a promising target for tumor progression.

Li K, Meng L, Yang Z, Hu W Front Pharmacol. 2024; 15:1514367.

PMID: 39720592 PMC: 11666513. DOI: 10.3389/fphar.2024.1514367.

Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.

Integration of virtual screening and proteomics reveals potential targets and pathways for ginsenoside Rg against myocardial ischemia.

Xie R, Li C, Zhong C, Lin Z, Li S, Chen B J Ginseng Res. 2024; 48(4):395-404.

PMID: 39036738 PMC: 11258380. DOI: 10.1016/j.jgr.2024.02.001.

References

Ortea I, Rodriguez-Ariza A, Chicano-Galvez E, Arenas Vacas M, Jurado Gamez B . Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics. 2016; 138:106-14. DOI: 10.1016/j.jprot.2016.02.010. View

Chmielecki J, Foo J, Oxnard G, Hutchinson K, Ohashi K, Somwar R . Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011; 3(90):90ra59. PMC: 3500629. DOI: 10.1126/scitranslmed.3002356. View

Hsu C, Hsu C, Hsueh C, Wang C, Wu Y, Wu C . Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma. Mol Cell Proteomics. 2016; 15(7):2396-410. PMC: 4937512. DOI: 10.1074/mcp.M115.057026. View

Birse C, Lagier R, Fitzhugh W, Pass H, Rom W, Edell E . Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015; 12(1):18. PMC: 4537594. DOI: 10.1186/s12014-015-9090-9. View

Cho W . Application of proteomics in non-small-cell lung cancer. Expert Rev Proteomics. 2015; 13(1):1-4. DOI: 10.1586/14789450.2016.1121813. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Leon G, MacDonagh L, Finn S, Cuffe S, Barr M . Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 2015; 158:71-90. DOI: 10.1016/j.pharmthera.2015.12.001. View

Shaw A, Gandhi L, Gadgeel S, Riely G, Cetnar J, West H . Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2015; 17(2):234-242. PMC: 4752892. DOI: 10.1016/S1470-2045(15)00488-X. View

Wang C, Wang C, Wu Y, Feng H, Liu P, Chang Y . Quantitative proteomics reveals a novel role of karyopherin alpha 2 in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer. J Proteome Res. 2015; 14(4):1739-51. DOI: 10.1021/pr501097a. View

10.

Luscombe N, Greenbaum D, Gerstein M . What is bioinformatics? A proposed definition and overview of the field. Methods Inf Med. 2001; 40(4):346-58. View

11.

Chang H, Huang H, Huang T, Yang P, Wang Y, Juan H . Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. Cancer Res. 2012; 72(18):4696-706. DOI: 10.1158/0008-5472.CAN-12-0567. View

12.

Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, Mikami S . Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics. 2009; 73(6):1089-99. DOI: 10.1016/j.jprot.2009.11.011. View

13.

Pan S, Aebersold R, Chen R, Rush J, Goodlett D, McIntosh M . Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res. 2008; 8(2):787-97. PMC: 2657955. DOI: 10.1021/pr800538n. View

14.

Voit E, Qi Z, Miller G . Steps of modeling complex biological systems. Pharmacopsychiatry. 2008; 41 Suppl 1:S78-84. DOI: 10.1055/s-2008-1080911. View

15.

Neverova I, Van Eyk J . Role of chromatographic techniques in proteomic analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 815(1-2):51-63. DOI: 10.1016/j.jchromb.2004.11.009. View

16.

Sutandy F, Qian J, Chen C, Zhu H . Overview of protein microarrays. Curr Protoc Protein Sci. 2013; Chapter 27:Unit 27.1. PMC: 3680110. DOI: 10.1002/0471140864.ps2701s72. View

17.

Kar G, Gursoy A, Keskin O . Human cancer protein-protein interaction network: a structural perspective. PLoS Comput Biol. 2009; 5(12):e1000601. PMC: 2785480. DOI: 10.1371/journal.pcbi.1000601. View

18.

Arike L, Peil L . Spectral counting label-free proteomics. Methods Mol Biol. 2014; 1156:213-22. DOI: 10.1007/978-1-4939-0685-7_14. View

19.

Hembrough T, Liao W, Hartley C, Ma P, Velcheti V, Lanigan C . Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib. Clin Chem. 2015; 62(1):252-61. PMC: 4760638. DOI: 10.1373/clinchem.2015.245860. View

20.

Wu Y, Hu C, Chien C, Chen Y, Huang H, Juan H . Quantitative proteomic analysis of human lung tumor xenografts treated with the ectopic ATP synthase inhibitor citreoviridin. PLoS One. 2013; 8(8):e70642. PMC: 3749231. DOI: 10.1371/journal.pone.0070642. View